Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

(2019) Davide Melisi et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma

(2019) Sandrine Faivre et al.   LIVER INTERNATIONAL

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

(2019) R.K. Kelley et al.   Clinical and Translational Gastroenterology

Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.

(2018) Vicki Leigh Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

(2018) Davide Melisi et al.   BRITISH JOURNAL OF CANCER

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

(2017) David Capper et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor

(2017) Florian Gessler et al.   World Neurosurgery

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

(2016) Alba A. Brandes et al.   NEURO-ONCOLOGY

Novel TGF-β inhibitors ready for prime time in onco-immunology

(2016) Armand de Gramont et al.   OncoImmunology

Temozolomide induced bone marrow Suppression-A single institution outcome analysis and review of the literature

(2015) Taxiarchis V. Kourelis et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

(2015) Armin Maier et al.   CELLULAR ONCOLOGY

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

(2015) Michael Lahn et al.   Drug Design Development and Therapy

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

(2014) Richard J. Kovacs et al.   Cardiovascular Toxicology

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

(2014) Jordi Rodon et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

(2014) Jordi Rodón et al.   INVESTIGATIONAL NEW DRUGS

Sustained CD4+T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide

(2014) Susannah Ellsworth et al.   OncoImmunology

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies

(2012) M J McCoy et al.   BRITISH JOURNAL OF CANCER

Blockade of TGF-  Signaling by the TGF R-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma

(2011) M. Zhang et al.   CANCER RESEARCH

Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

(2011) Stuart A. Grossman et al.   CLINICAL CANCER RESEARCH

Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme

(2011) C. E. Fadul et al.   NEURO-ONCOLOGY

Roles for the type III TGF-β receptor in human cancer

(2010) Catherine E. Gatza et al.   CELLULAR SIGNALLING

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY